Search International and National Patent Collections

1. (WO2018220099) TYPE II ANTI-CD20 ANTIBODY AND ANTI-CD20/CD3 BISPECIFIC ANTIBODY FOR TREATMENT OF CANCER

Pub. No.:    WO/2018/220099    International Application No.:    PCT/EP2018/064319
Publication Date: Fri Dec 07 00:59:59 CET 2018 International Filing Date: Fri Jun 01 01:59:59 CEST 2018
IPC: C07K 16/28
A61K 39/395
C07K 16/30
Applicants: F. HOFFMANN-LA ROCHE AG
HOFFMANN-LA ROCHE INC.
Inventors: BACAC, Marina
COLOMBETTI, Sara
KLEIN, Christian
SAM, Johannes
UMAÑA, Pablo
Title: TYPE II ANTI-CD20 ANTIBODY AND ANTI-CD20/CD3 BISPECIFIC ANTIBODY FOR TREATMENT OF CANCER
Abstract:
The present invention relates to methods of treating a disease, and methods for reduction of cytokine release associated with the administration of a T-cell activating therapeutic agent. The present invention in particular relates to a Type II anti-CD20 antibody for the use in a method for treating or delaying progression of cancer of an individual, wherein the Type II anti-CD20 antibody is used in combination with an anti-CD20/anti-CD3 bispecific antibody.